These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 38381257)
21. Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma. Choi J; Kim SH; Ahn SS; Choi HJ; Yoon HI; Cho JH; Roh TH; Kang SG; Chang JH; Suh CO Sci Rep; 2020 Feb; 10(1):2086. PubMed ID: 32034238 [TBL] [Abstract][Full Text] [Related]
22. Influence of socioeconomic status on clinical outcomes of diffuse midline glioma and diffuse intrinsic pontine glioma. Lee JH; Holste KG; Bah MG; Franson AT; Garton HJL; Maher CO; Muraszko KM J Neurosurg Pediatr; 2024 Jun; 33(6):507-515. PubMed ID: 38489807 [TBL] [Abstract][Full Text] [Related]
23. Diagnostic challenges, management and outcomes of midline low-grade gliomas. Waqar M; Hanif S; Rathi N; Das K; Zakaria R; Brodbelt AR; Walker C; Jenkinson MD J Neurooncol; 2014 Nov; 120(2):389-98. PubMed ID: 25096797 [TBL] [Abstract][Full Text] [Related]
24. Lower expression of Bax predicts poor clinical outcome in patients with glioma after curative resection and radiotherapy/chemotherapy. Wang PG; Li YT; Pan Y; Gao ZZ; Guan XW; Jia L; Liu FT J Neurooncol; 2019 Jan; 141(1):71-81. PubMed ID: 30446901 [TBL] [Abstract][Full Text] [Related]
25. Administration of Valproic Acid Improves the Survival of Patients with Glioma Treated with Postoperative Radiotherapy. Wang G; Guan S; Yang X; Sun S; Huang B; Li X Oncol Res Treat; 2022; 45(11):650-659. PubMed ID: 35988539 [TBL] [Abstract][Full Text] [Related]
26. Neutrophil/Lymphocyte Ratio Is an Independent Prognostic Factor in Elderly Patients with High-Grade Gliomas. Gan Y; Zhou X; Niu X; Li J; Wang T; Zhang H; Yang Y; Liu Y; Mao Q World Neurosurg; 2019 Jul; 127():e261-e267. PubMed ID: 30898756 [TBL] [Abstract][Full Text] [Related]
27. The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study. Di Nunno V; Lombardi G; Simonelli M; Minniti G; Mastronuzzi A; Di Ruscio V; CorrĂ M; Padovan M; Maccari M; Caccese M; Simonetti G; Berlendis A; Farinotti M; Pollo B; Antonelli M; Di Muzio A; Dipasquale A; Asioli S; De Biase D; Tosoni A; Silvani A; Franceschi E J Neurooncol; 2024 Mar; 167(1):145-154. PubMed ID: 38457090 [TBL] [Abstract][Full Text] [Related]
28. Apatinib combined with temozolomide in diffuse midline glioma: a novel and effective therapy. Li YA; Zhao C; Ge JJ; Li C; Xue FJ; Qi SP; Zhao C; Kong CC; Zhang JP BMC Cancer; 2024 Jun; 24(1):754. PubMed ID: 38907215 [TBL] [Abstract][Full Text] [Related]
29. Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. Bell EH; Zhang P; Fisher BJ; Macdonald DR; McElroy JP; Lesser GJ; Fleming J; Chakraborty AR; Liu Z; Becker AP; Fabian D; Aldape KD; Ashby LS; Werner-Wasik M; Walker EM; Bahary JP; Kwok Y; Yu HM; Laack NN; Schultz CJ; Gray HJ; Robins HI; Mehta MP; Chakravarti A JAMA Oncol; 2018 Oct; 4(10):1405-1409. PubMed ID: 29955793 [TBL] [Abstract][Full Text] [Related]
30. Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma. Sirachainan N; Pakakasama S; Visudithbhan A; Chiamchanya S; Tuntiyatorn L; Dhanachai M; Laothamatas J; Hongeng S Neuro Oncol; 2008 Aug; 10(4):577-82. PubMed ID: 18559468 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of the Prognosis of Neuroglioma Based on Dynamic Magnetic Resonance Enhancement. Li F; Zhang Y; Wang N; Song C; Gao Y; Diao X; Zhang H World Neurosurg; 2020 Jun; 138():663-671. PubMed ID: 31981784 [TBL] [Abstract][Full Text] [Related]
32. A nomogram combining inflammatory markers and clinical factors predicts survival in patients with diffuse glioma. Yan P; Li JW; Mo LG; Huang QR Medicine (Baltimore); 2021 Nov; 100(47):e27972. PubMed ID: 34964788 [TBL] [Abstract][Full Text] [Related]
33. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations. Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806 [TBL] [Abstract][Full Text] [Related]
34. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840 [TBL] [Abstract][Full Text] [Related]
35. [Survival of newly diagnosed malignant glioma patients on combined modality therapy]. Yang QY; Shen D; Sai K; Jiang XB; Ke C; Zhang XH; Mou YG; Chen ZP Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(1):8-10. PubMed ID: 23578444 [TBL] [Abstract][Full Text] [Related]
36. Outcome and characteristics of patients with adult grade 4 diffuse gliomas changing sites of treatment. Forster MT; Hug M; Geissler M; Voss M; Weber K; Hoelter MC; Seifert V; Czabanka M; Steinbach JP J Cancer Res Clin Oncol; 2023 Jan; 149(1):111-119. PubMed ID: 36348019 [TBL] [Abstract][Full Text] [Related]
38. Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma. Jo J; Williams B; Smolkin M; Wintermark M; Shaffrey ME; Lopes MB; Schiff D J Neurooncol; 2014 Oct; 120(1):155-61. PubMed ID: 25038848 [TBL] [Abstract][Full Text] [Related]
39. Prognostic Factors for Survival Outcome of High-Grade Multicentric Glioma. Wang T; Niu X; Gao T; Zhao L; Li J; Gan Y; Liu Y; Mao Q World Neurosurg; 2018 Apr; 112():e269-e277. PubMed ID: 29337167 [TBL] [Abstract][Full Text] [Related]